GlaxoSmithKline (GSK) has been undergoing some significant restructuring over the recent past in a bid to cement its position in various core operations.
The company has formed key partnerships in the production of various drugs, as it seeks to establish vibrant access to emerging markets and regions of East Asia. GSK's recently approved Anoro Ellipta seems to set the stage for more approvals of some of the company's respiratory products, as Japan paints a green light for the product in prospective markets.
Glaxo's recent performance appeared muted, and its return on investment YTD has not been the most impressive. However, its high dividend yield makes a lucrative cushion for the failure to deliver capital gains in tandem with industry peers.
Swapping Oncology for Vaccines makes sense